T. J. Washburn's most recent trade in Agios Pharmaceuticals Inc was a trade of 8,085 Restricted stock units done . Disclosure was reported to the exchange on March 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 8,085 | 8,085 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 6,142 | 6,142 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,450 | 10,141 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,450 | 4,900 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,350 | 8,388 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,350 | 2,350 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 777 | 6,269 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 777 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 727 | 9,414 (0%) | 0% | 35.5 | 25,838 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 697 | 7,691 (0%) | 0% | 35.5 | 24,771 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 231 | 6,038 (0%) | 0% | 35.5 | 8,210 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 6,896 | 7,709 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 6,896 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 34.39 per share. | 01 Feb 2025 | 2,272 | 5,437 (0%) | 0% | 34.4 | 78,134 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 56.09 per share. | 08 Nov 2024 | 772 | 813 (0%) | 0% | 56.1 | 43,301 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 44.39 per share. | 03 Jun 2024 | 1,362 | 1,524 (0%) | 0% | 44.4 | 60,459 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 31.75 per share. | 05 Mar 2024 | 1,913 | 2,886 (0%) | 0% | 31.8 | 60,738 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 7,350 | 7,350 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,350 | 5,718 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,350 | 4,700 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 919 | 4,799 (0%) | 0% | 32.6 | 29,932 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 777 | 3,663 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 777 | 777 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 295 | 3,368 (0%) | 0% | 32.6 | 9,608 | Common stock |
| Agios Pharmaceuticals Inc | Washburn J. T. | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 26.63 per share. | 20 Feb 2024 | 504 | 2,741 (0%) | 0% | 26.6 | 13,422 | Common stock |
| Agios Pharmaceuticals Inc | Washburn T. J. | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 777 | 3,518 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Washburn J. T. | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 777 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | J. Washburn T. | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 12 Feb 2024 | 273 | 3,245 (0%) | 0% | 25.1 | 6,863 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.39 per share. | 07 Aug 2023 | 2,918 | 2,741 (0%) | 0% | 25.4 | 74,096 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2023 | 4,150 | 6,891 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2023 | 4,150 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 26.26 per share. | 01 Aug 2023 | 1,232 | 5,659 (0%) | 0% | 26.3 | 32,352 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 24.29 per share. | 03 Mar 2023 | 504 | 2,741 (0%) | 0% | 24.3 | 12,242 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 7,050 | 7,050 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 777 | 3,518 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 777 | 1,554 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.31 per share. | 01 Mar 2023 | 273 | 3,245 (0%) | 0% | 25.3 | 6,910 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 27.21 per share. | 16 Feb 2023 | 233 | 2,668 (0%) | 0% | 27.2 | 6,340 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 14 Feb 2023 | 504 | 2,901 (0%) | 0% | 28.6 | 14,409 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 360 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 360 | 3,532 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 14 Feb 2023 | 127 | 3,405 (0%) | 0% | 28.9 | 3,672 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 6,896 | 6,896 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 777 | 777 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 777 | 3,445 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.44 per share. | 01 Feb 2023 | 273 | 3,172 (0%) | 0% | 28.4 | 7,764 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 2,331 | 2,331 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 1,165 | 1,165 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 25 Feb 2022 | 108 | 2,549 (0%) | 0% | 30 | 3,240 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 167 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 167 | 2,716 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 22 Feb 2022 | 59 | 2,657 (0%) | 0% | 29.1 | 1,716 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 30.81 per share. | 16 Feb 2022 | 233 | 2,549 (0%) | 0% | 30.8 | 7,179 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 31.25 per share. | 14 Feb 2022 | 504 | 2,782 (0%) | 0% | 31.3 | 15,750 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 360 | 360 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 360 | 3,413 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.50 per share. | 14 Feb 2022 | 127 | 3,286 (0%) | 0% | 30.5 | 3,874 | Common stock |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 777 | 1,554 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 777 | 3,292 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 273 | 3,019 (0%) | 0% | 31.4 | 8,579 | Common stock |